Oxford Biomedica PLC Findings Reported by Novartis on CTL-019 at ASH
December 05 2016 - 5:25AM
RNS Non-Regulatory
TIDMOXB
Oxford Biomedica PLC
05 December 2016
Oxford BioMedica Notes Findings Reported by Novartis on CTL-019
at 58th American Society of Hematology Annual Meeting
Oxford, UK & London, UK- 5 December 2016: Oxford BioMedica
plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene
and cell therapy group, today notes the findings reported by
Novartis on their clinical trial (ELIANA) evaluating the efficacy
and safety of CTL019, an investigational chimeric antigen receptor
T cell (CAR T) therapy, in relapsed/refractory (r/r) pediatric and
young adult patients with B-cell acute lymphoblastic leukemia
(ALL). Oxford BioMedica produces the lentiviral vector expressing
CTL019 and has a CAR-T partnership with Novartis.
The findings were presented during an oral session on Saturday
3rd December 2016 at the 58th American Society of Hematology (ASH)
annual meeting (Abstract #221, December 3, 4:00-5:30 p.m.).
Novartis reported that the global Phase II study found that 82% (41
of 50) of infused patients achieved complete remission or complete
remission with incomplete blood count recovery at three months post
CTL019 infusion. For all patients with complete remission, no
minimal residual disease was detected. In addition, the estimated
relapse-free rate among responders was 60% (95% CI: 36, 78) six
months after infusion with CTL019. Novartis confirmed their
intention to file CTL019 with the US Food and Drug Administration
(FDA) in early 2017 for pediatric and young adult patients with r/r
B-cell ALL.
John Dawson, Chief Executive Officer of Oxford BioMedica,
commented: "We are pleased that Novartis
has reported exciting progress with its investigational therapy
CTL-019, and that Novartis confirm their commitment to advancing
CTL019 and working closely with the FDA and EMA in the coming
months."
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Notes to editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and
ex-vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
250 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZMMGZGKZGVZM
(END) Dow Jones Newswires
December 05, 2016 05:25 ET (10:25 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2023 to Apr 2024